{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141632,"version":"4.3.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001381","name":"PMO | National Research Foundation Singapore","doi-asserted-by":"publisher","award":["NRF-NRFI06-2020-0004"],"award-info":[{"award-number":["NRF-NRFI06-2020-0004"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ineos Oxford Institute for Antimicrobial Research"},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI054193"],"award-info":[{"award-number":["R37AI054193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI139465"],"award-info":[{"award-number":["R01AI139465"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pretomanid is a unique anti-tuberculosis agent that inhibits both cell-wall synthesis and bioenergetics in\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    . While targeting the cell wall triggers a rapid bactericidal effect on replicating mycobacteria, the release of nitric oxide is linked to bactericidal potency against antibiotic-tolerant, non-replicating subpopulations through interference with the electron transport chain. Nonetheless, the specific molecular target(s) of the drug remain unknown. Through the utilization of genetic and chemical biology approaches, we present evidence that pretomanid inhibits both the cytochrome\n                    <jats:italic>bcc:aa<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>3<\/jats:italic>\n                    <\/jats:sub>\n                    and\n                    <jats:italic>bd<\/jats:italic>\n                    oxidase respiratory branches. This property leads to a pronounced synergy with telacebec (Q203), a clinical-stage drug targeting the cytochrome\n                    <jats:italic>bcc:aa<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>3<\/jats:italic>\n                    <\/jats:sub>\n                    , while concurrently curtailing the emergence of resistance to pretomanid. Furthermore, the incorporation of the cytochrome\n                    <jats:italic>bd<\/jats:italic>\n                    oxidase inhibitor ND-011992 resulted in a triple drug combination highly bactericidal against antibiotic-tolerant, non-replicating as well as replicating\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    . The combination of pretomanid and drugs targeting the terminal oxidases holds the potential to serve as the cornerstone for an efficacious sterilizing drug regimen against tuberculosis.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00378-9","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:43:43Z","timestamp":1770371023000},"page":"1009-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A bactericidal tuberculosis drug regimen driven by inhibition of the terminal oxidases by pretomanid"],"prefix":"10.1038","volume":"18","author":[{"given":"Nurlilah Ab","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-931X","authenticated-orcid":false,"given":"Samsher","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Delos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-5584","authenticated-orcid":false,"given":"Garrett C","family":"Moraski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-8214","authenticated-orcid":false,"given":"Marvin J","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-8873","authenticated-orcid":false,"given":"Kevin","family":"Pethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"378_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, G\u00f6hlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223\u2013227","journal-title":"Science"},{"key":"378_CR2","doi-asserted-by":"publisher","first-page":"16774","DOI":"10.1073\/pnas.0405368101","volume":"101","author":"F Antunes","year":"2004","unstructured":"Antunes F, Boveris A, Cadenas E (2004) On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide. Proc Natl Acad Sci USA 101:16774\u201316779","journal-title":"Proc Natl Acad Sci USA"},{"key":"378_CR3","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1128\/AAC.03486-14","volume":"58","author":"K Arora","year":"2014","unstructured":"Arora K, Ochoa-Montano B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LA, Ray PC et al (2014) Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:6962\u20136965","journal-title":"Antimicrob Agents Chemother"},{"key":"378_CR4","first-page":"e01292","volume":"11","author":"K Bayly","year":"2021","unstructured":"Bayly K, Cordero PRF, Kropp A, Huang C, Schittenhelm RB, Grinter R, Greening C (2021) Mycobacteria tolerate carbon monoxide by remodeling their respiratory chain. mSystems 11:e01292\u201320","journal-title":"mSystems"},{"key":"378_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12956-2","volume":"10","author":"T Beites","year":"2019","unstructured":"Beites T, O\u2019Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang HJ, Sutphen ML, Weiner DM, Dayao EK et al (2019) Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat Commun 10:4970","journal-title":"Nat Commun"},{"key":"378_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1365-2958.2002.02779.x","volume":"43","author":"JC Betts","year":"2002","unstructured":"Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717\u2013731","journal-title":"Mol Microbiol"},{"key":"378_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1473-3099(19)30489-X","volume":"19","author":"T Burki","year":"2019","unstructured":"Burki T (2019) BPaL approved for multidrug-resistant tuberculosis. Lancet Infect Dis 19:1063\u20131064","journal-title":"Lancet Infect Dis"},{"key":"378_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0968-0004(01)02035-7","volume":"27","author":"CE Cooper","year":"2002","unstructured":"Cooper CE (2002) Nitric oxide and cytochrome oxidase: substrate, inhibitor or effector? Trends Biochem Sci 27:33\u201339","journal-title":"Trends Biochem Sci"},{"key":"378_CR9","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMc1913327","volume":"382","author":"VR de Jager","year":"2020","unstructured":"de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, van der Merwe L, Choi J, Nam K, Diacon AH (2020) Telacebec (Q203), a new antituberculosis agent. N Engl J Med 382:1280\u20131281","journal-title":"N Engl J Med"},{"key":"378_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijtb.2020.09.003","volume":"68","author":"U Deb","year":"2021","unstructured":"Deb U, Biswas S (2021) Pretomanid: the latest USFDA-approved anti-tuberculosis drug. Indian J Tuberc 68:287\u2013291","journal-title":"Indian J Tuberc"},{"key":"378_CR11","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1172\/JCI119473","volume":"99","author":"FC Fang","year":"1997","unstructured":"Fang FC (1997) Perspectives series: host\/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 99:2818\u20132825","journal-title":"J Clin Invest"},{"key":"378_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ng.2656","volume":"45","author":"CB Ford","year":"2013","unstructured":"Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM (2013) Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45:784\u2013790","journal-title":"Nat Genet"},{"key":"378_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1099\/mic.0.033084-0","volume":"156","author":"M Gengenbacher","year":"2010","unstructured":"Gengenbacher M, Rao SPS, Pethe K, Dick T (2010) Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 156:81\u201387","journal-title":"Microbiology"},{"key":"378_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.febslet.2011.07.035","volume":"586","author":"A Giuffre","year":"2012","unstructured":"Giuffre A, Borisov VB, Mastronicola D, Sarti P, Forte E (2012) Cytochrome bd oxidase and nitric oxide: from reaction mechanisms to bacterial physiology. FEBS Lett 586:622\u2013629","journal-title":"FEBS Lett"},{"key":"378_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1358\/dot.2013.49.6.1970865","volume":"49","author":"J Gras","year":"2013","unstructured":"Gras J (2013) Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults. Drugs Today (Barc) 49:353\u2013361","journal-title":"Drugs Today (Barc)"},{"key":"378_CR16","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00308-15","volume":"59","author":"HL Haver","year":"2015","unstructured":"Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P (2015) Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:5316\u20135323","journal-title":"Antimicrob Agents Chemother"},{"key":"378_CR17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/febs.13715","volume":"283","author":"A Hotra","year":"2016","unstructured":"Hotra A, Suter M, Biukovic G, Ragunathan P, Kundu S, Dick T, Gruber G (2016) Deletion of a unique loop in the mycobacterial F-ATP synthase gamma subunit sheds light on its inhibitory role in ATP hydrolysis-driven H(+) pumping. FEBS J 283:1947\u20131961","journal-title":"FEBS J"},{"key":"378_CR18","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1073\/pnas.1706139114","volume":"114","author":"NP Kalia","year":"2017","unstructured":"Kalia NP, Hasenoehrl EJ, Ab Rahman NB, Koh VH, Ang MLT, Sajorda DR, Hards K, Gruber G, Alonso S, Cook GM et al (2017) Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection. Proc Natl Acad Sci USA 114:7426\u20137431","journal-title":"Proc Natl Acad Sci USA"},{"key":"378_CR19","doi-asserted-by":"crossref","unstructured":"Komm OD, Tyagi S, Garcia A, Almeida D, Chang Y, Li SY, Castillo JR, Converse PJ, Black T, Fotouhi N et al (2024) Contribution of telacebec to novel drug regimens in a murine tuberculosis model. Antimicrob Agents Chemother 69:e0096224","DOI":"10.1101\/2024.06.27.601059"},{"key":"378_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12393","volume":"7","author":"DA Lamprecht","year":"2016","unstructured":"Lamprecht DA, Finin PM, Rahman MA, Cumming BM, Russell SL, Jonnala SR, Adamson JH, Steyn AJ (2016) Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat Commun 7:12393","journal-title":"Nat Commun"},{"key":"378_CR21","doi-asserted-by":"publisher","first-page":"106068","DOI":"10.1016\/j.ijantimicag.2020.106068","volume":"56","author":"S Laurent","year":"2020","unstructured":"Laurent S, Zakham F, Bertelli C, Merz L, Nicod L, Mazza-Stalder J, Greub G, Jaton K, Opota O (2020) Genome sequencing of Mycobacterium tuberculosis clinical isolates revealed isoniazid resistance mechanisms undetected by conventional molecular methods. Int J Antimicrob Agents 56:106068","journal-title":"Int J Antimicrob Agents"},{"key":"378_CR22","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013207","volume":"13","author":"BS Lee","year":"2021","unstructured":"Lee BS, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMS, Manimekalai MSS, Koh VH et al (2021) Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. EMBO Mol Med 13:e13207","journal-title":"EMBO Mol Med"},{"key":"378_CR23","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1074\/jbc.RA118.005732","volume":"294","author":"BS Lee","year":"2019","unstructured":"Lee BS, Kalia NP, Jin XEF, Hasenoehrl EJ, Berney M, Pethe K (2019) Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria. J Biol Chem 294:1936\u20131943","journal-title":"J Biol Chem"},{"key":"378_CR24","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1086\/515254","volume":"177","author":"Z Li","year":"1998","unstructured":"Li Z, Kelley C, Collins F, Rouse D, Morris S (1998) Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 177:1030\u20131035","journal-title":"J Infect Dis"},{"key":"378_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/dkab505","volume":"77","author":"SE Mudde","year":"2022","unstructured":"Mudde SE, Upton AM, Lenaerts A, Bax HI, De Steenwinkel JEM (2022) Delamanid or pretomanid? A Solomonic judgement!. J Antimicrob Chemother 77:880\u2013902","journal-title":"J Antimicrob Chemother"},{"key":"378_CR26","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","volume":"19","author":"K Pethe","year":"2013","unstructured":"Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J et al (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19:1157","journal-title":"Nat Med"},{"key":"378_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1060","volume":"1","author":"K Pethe","year":"2010","unstructured":"Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J et al (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57","journal-title":"Nat Commun"},{"key":"378_CR28","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"SP Rao","year":"2008","unstructured":"Rao SP, Alonso S, Rand L, Dick T, Pethe K (2008) The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 105:11945\u201311950","journal-title":"Proc Natl Acad Sci USA"},{"key":"378_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","volume":"74","author":"NJ Ryan","year":"2014","unstructured":"Ryan NJ, Lo JH (2014) Delamanid: first global approval. Drugs 74:1041\u20131045","journal-title":"Drugs"},{"key":"378_CR30","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3389\/fmicb.2018.01898","volume":"9","author":"A Shetty","year":"2018","unstructured":"Shetty A, Dick T (2018) Mycobacterial cell wall synthesis inhibitors cause lethal ATP burst. Front Microbiol 9:1898","journal-title":"Front Microbiol"},{"key":"378_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","volume":"322","author":"R Singh","year":"2008","unstructured":"Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L et al (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322:1392\u20131395","journal-title":"Science"},{"key":"378_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN et al (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962\u2013966","journal-title":"Nature"},{"key":"378_CR33","unstructured":"WHO (2023) Global tuberculosis report 2023. WHO, Geneva"},{"key":"378_CR34","doi-asserted-by":"publisher","first-page":"e01841","DOI":"10.1128\/AAC.01841-18","volume":"63","author":"S Zeng","year":"2019","unstructured":"Zeng S, Soetaert K, Ravon F, Vandeput M, Bald D, Kauffmann JM, Mathys V, Wattiez R, Fontaine V (2019) Isoniazid bactericidal activity involves electron transport chain perturbation. Antimicrob Agents Chemother 63:e01841\u201318","journal-title":"Antimicrob Agents Chemother"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00378-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:44:21Z","timestamp":1779065061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00378-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,13]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00378-9","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}